HIV Research Highlights from First Day of CROI 2018
. . . Short-course regimen for TB prevention—A one-month antibiotic regimen to prevent active tuberculosis (TB) disease was at least as safe and effective as the standard nine-month therapy for people living with HIV, according to the results of a large international clinical trial. These findings could be a “game changer” for helping people stay TB-free, remarked Dr. Dieffenbach, noting that TB is the single biggest killer of HIV+ people around the globe. Adults and adolescents in the trial were more likely to complete the short-course regimen—consisting of daily doses of the antibiotics rifapentine and isoniazid for four weeks—than the standard nine-month regimen of daily isoniazid, according to the findings presented by Richard Chaisson, MD, of Johns Hopkins. The study was sponsored by NIAID and conducted by the NIAID-funded AIDS Clinical Trials Group (ACTG). Read the study abstract; read NIAID’s news release about this research . . .